CTLA4 and neoplasm: Similarly, the first report on CTLA-4 blockade (negative regulator of T-cell activation [113]) in anti-tumor immunity was demonstrated in 1996 [114] and the first clinical report of CTLA-4 against melanoma in 2003 [115,116].